共 134 条
[11]
Al-Askari S(1986)Meta-analysis in clinical trials Control Clin Trials 7 177-560
[12]
Morales P(2003)Measuring inconsistency in meta-analyses BMJ 327 557-3140
[13]
Minasian LM(2003)Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a cytokine working group randomized trial J Clin Oncol 21 3133-2566
[14]
Motzer RJ(1996)Adjuvant immunotherapy treatment of renal carcinoma patients with autologous tumor cells and bacillus Calmette-Guerin: five-year results of a prospective randomized study Cancer 77 2560-599
[15]
Gluck L(2004)Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomised controlled trial Lancet 363 594-431
[16]
Mazumdar M(2001)Interferon adjuvant to radical nephrectomy in Robson stages II and III renal cell carcinoma: a multicentric randomized study J Clin Oncol 19 425-154
[17]
Vlamis V(2008)An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial Lancet 372 145-341
[18]
Krown SE(2009)Randomized trial of adjuvant thalidomide versus observation in patients with completely resected high-risk renal cell carcinoma Urology 73 337-582
[19]
Fisher RI(2006)Adjuvant therapy for renal cell carcinoma Semin Oncol 33 576-66
[20]
Rosenberg SA(2009)Adjuvant and neoadjuvant small-molecule targeted therapy in high-risk renal cell carcinoma Curr Oncol 16 S60-undefined